$234.00
1.650.71%
最終更新: Sep 30, 9:09 AM
Benzinga
Benzinga
Benzinga
水曜日, 9 30
Jazz Pharmaceuticals PLC
JAZZNASDAQ
Jazz Pharmaceuticals Earnings & Forecasts
Jazz Pharmaceuticals (JAZZ) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Jazz Pharmaceuticals Guidance
Jazz Pharmaceuticals (JAZZ) は、8 3, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$4.6B - $4.75Bの範囲と予想しています。
以前のガイダンスと比較して、Jazz Pharmaceuticalsは売上高予測を以前の範囲である引き上げから$4.25B - $4.5Bに引き上げました。
Jazz Pharmaceuticalsは、20から11 9, 2022の間に8 3, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 9 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $5.94 | $4.49 | $6.16 | $5.43 |
| Actual | $5.71 | $6.34 | $6.64 | $8.13 |
| Surprise | -3.87% | +41.2% | +7.79% | +49.7% |
| Revenue | ||||
| Estimate | $1.11B | $977.6M | $1.17B | $1.11B |
| Actual | $1.21B | $1.61B | $1.20B | $1.13B |
| Surprise | +9.06% | +64.6% | +2.21% | +1.89% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $6.29 | $6.33 | $5.23 | $5.68 |
| Revenue | ||||
| Consensus | $1.21B | $1.23B | — | — |
Earnings & Guidance News
Benzinga
© 2026 Benzinga | All Rights Reserved